BioCentury | Dec 13, 2016
Distillery Therapeutics

Infectious disease

...published online Nov. 14, 2016 doi:10.1038/nmicrobiol.2016.211 CONTACT: Scott Filler, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Inc., Novato, Calif. e-mail: maoyagi-scharber@bmrn.com Contact: Patricia I. Dickson, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Jun 30, 2014
Company News

NovaDigm, Harbor-UCLA Medical Center deal

...albicans hyphally regulated cell wall protein 1 ( Hyr1 ), a Candida vaccine antigen, from Harbor-UCLA Medical Center’s...
...timeline. NovaDigm said financial terms are not disclosed. NovaDigm Therapeutics Inc. , Grand Forks, N.D. Harbor-UCLA Medical Center...
BioCentury | Sep 6, 2012
Cover Story

New home for bromodomains

...in the Division of Endocrinology & Metabolism at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...Boston, Mass. The George Washington University School of Medicine and Health Sciences , Washington, D.C. Harbor-UCLA Medical Center...
BioCentury | Mar 19, 2012
Regulation

Feasible, perhaps not relevant

...so," said Brad Spellberg, professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...Stonington, Conn. Cubist Pharmaceutical Inc. (NASDAQ:CBST), Lexington, Mass. European Medicines Agency (EMA), London, U.K. Harbor-UCLA Medical Center...
BioCentury | Dec 19, 2011
Regulation

Europe speeds away

...Inc. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...New York, N.Y. Furiex Pharmaceuticals Inc. (NASDAQ:FURX), Morrisville, N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Harbor-UCLA Medical Center...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

...therapy against mold infections; available for licensing from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...online May 17, 2010; doi:10.1172/JCI42164 Contact: Ashraf S. Ibrahim, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Aug 7, 2008
Cover Story

Tolerating Enzyme Delivery

...the JCI paper and assistant professor and researcher in the Department of Pediatrics at the Harbor-UCLA Medical Center...
...Cincinnati, Ohio Duke University Medical Center , Durham, N.C. Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass. Harbor-UCLA Medical Center...
BioCentury | Jul 21, 2008
Regulation

Inferiority muddle

...John Edwards, a temporary voting member and chief of the division of infectious diseases at Harbor-UCLA Medical Center...
BioCentury | Sep 10, 2007
Product Development

Paradigm shift in AIDS

...especially Isentress, will be incorporated into combination therapies. Eric Daar, chief of HIV medicine at Harbor-UCLA Medical Center...
Items per page:
1 - 10 of 16
BioCentury | Dec 13, 2016
Distillery Therapeutics

Infectious disease

...published online Nov. 14, 2016 doi:10.1038/nmicrobiol.2016.211 CONTACT: Scott Filler, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Inc., Novato, Calif. e-mail: maoyagi-scharber@bmrn.com Contact: Patricia I. Dickson, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Jun 30, 2014
Company News

NovaDigm, Harbor-UCLA Medical Center deal

...albicans hyphally regulated cell wall protein 1 ( Hyr1 ), a Candida vaccine antigen, from Harbor-UCLA Medical Center’s...
...timeline. NovaDigm said financial terms are not disclosed. NovaDigm Therapeutics Inc. , Grand Forks, N.D. Harbor-UCLA Medical Center...
BioCentury | Sep 6, 2012
Cover Story

New home for bromodomains

...in the Division of Endocrinology & Metabolism at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...Boston, Mass. The George Washington University School of Medicine and Health Sciences , Washington, D.C. Harbor-UCLA Medical Center...
BioCentury | Mar 19, 2012
Regulation

Feasible, perhaps not relevant

...so," said Brad Spellberg, professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...Stonington, Conn. Cubist Pharmaceutical Inc. (NASDAQ:CBST), Lexington, Mass. European Medicines Agency (EMA), London, U.K. Harbor-UCLA Medical Center...
BioCentury | Dec 19, 2011
Regulation

Europe speeds away

...Inc. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...New York, N.Y. Furiex Pharmaceuticals Inc. (NASDAQ:FURX), Morrisville, N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Harbor-UCLA Medical Center...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

...therapy against mold infections; available for licensing from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
...online May 17, 2010; doi:10.1172/JCI42164 Contact: Ashraf S. Ibrahim, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center...
BioCentury | Aug 7, 2008
Cover Story

Tolerating Enzyme Delivery

...the JCI paper and assistant professor and researcher in the Department of Pediatrics at the Harbor-UCLA Medical Center...
...Cincinnati, Ohio Duke University Medical Center , Durham, N.C. Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass. Harbor-UCLA Medical Center...
BioCentury | Jul 21, 2008
Regulation

Inferiority muddle

...John Edwards, a temporary voting member and chief of the division of infectious diseases at Harbor-UCLA Medical Center...
BioCentury | Sep 10, 2007
Product Development

Paradigm shift in AIDS

...especially Isentress, will be incorporated into combination therapies. Eric Daar, chief of HIV medicine at Harbor-UCLA Medical Center...
Items per page:
1 - 10 of 16